Non-invasive prostate MiRNA Scientific offers a non-invasive urine liquid biopsy test (miR Sentinel Prostate Cancer Test) that detects, classifies, and monitors prostate cancer molecularly, presenting a compelling entry point for Urology and Oncology clinics seeking value-based care solutions.

Early-stage market fit The company focuses on precision healthcare with an initial emphasis on urological cancers, suggesting opportunities to partner with urology centers, cancer centers, and labs seeking innovative surveillance and early detection tools.

Value-based care With a proprietary miR Disease Management Platform aimed at transforming value-based cancer care, there is potential to align with payors and health systems pursuing cost-effective, outcome-driven diagnostic strategies.

Growth readiness Revenue is in the range of 10-25 million, indicating a growing but mid-stage scale suitable for collaboration on larger pilot programs, multi-site deployments, or expanded test panels as capacity increases.

Tech and privacy readiness A web-enabled tech stack and cloud infrastructure (Google Hosted Libraries, Cloudflare, etc.) coupled with data management capabilities suggest partnerships with CROs, CLIA-certified labs, or digital health platforms needing secure integration and compliance-ready workflows.